Are implantable cardioverter- defibrillators cost-effective?
Sudden cardiac deaths account for a large number of cardiovascular deaths, and ventricular tachyarrhythmias are implicated in many of these. In survivors of sudden cardiac deaths and other selected groups of patients, implantable cardioverter-defibrillators (ICDs) have been shown to have significant survival benefits in randomized controlled trials. The incremental costs for each extra year of survival conferred by ICDs were compared to the cost of antiarrhythmic drug therapy in some of these trials. In patients with nonsustained ventricular tachycardia with low ejection fraction (< 35%) and inducible sustained ventricular tachycardia on programmed electrical stimulation (nonsuppressible by procainamide), the incremental costs of ICD therapy amounted to $27,000 per life-year saved, compared with drug therapy. These costs may be acceptable increments for adaptation of the new technology in view of the definite survival advantage conferred by ICDs. Evolving technology may further reduce these costs by development of better devices with longer battery life.
Naik
A M
AM
Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 5342, Los Angeles, CA 90048, USA. c.peter@cshs.org
Peter
C T
CT
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D016757:Death, Sudden, Cardiac / Q000517:prevention & control*; D017147:Defibrillators, Implantable / Q000191:economics*; D022062:Electrophysiologic Techniques, Cardiac; D006801:Humans; D008390:Markov Chains; D011788:Quality of Life; D017180:Tachycardia, Ventricular / Q000517:prevention & control*
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone